Clinical Cancer Drugs
Title:Meet Our Editorial Board Member
Volume: 6
Author(s): K.X. Sun
Affiliation:
Export Options
About this article
Cite this article as:
Sun K.X. , Meet Our Editorial Board Member , Clinical Cancer Drugs 2019; 6 (1) . https://dx.doi.org/10.2174/2212697X0601190725112327
DOI https://dx.doi.org/10.2174/2212697X0601190725112327 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |
26
4
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry A Steroidal Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitor Triggers Pro-apoptotic Signaling and Induces Apoptosis in Prostate and Lung Tumor Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery RNA Interference as Therapeutics for Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry New Therapeutic Platforms for the Treatment of Epithelial and Cutaneous Lesions
Current Drug Delivery Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Rationale for Designing of Antigen-Specific Immune Therapy Including Dendritic Cell-Based Therapy in Patients with Chronic Hepatitis B Virus Infection
Anti-Infective Agents in Medicinal Chemistry Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science MicroRNAs: Association with Radioresistant and Potential Uses of Natural Remedies as Green Gene Therapeutic Approaches
Current Gene Therapy